EX-99.1 2 tm2617139d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index MORRISVILLE, N.C. (June 8, 2026) - Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026. Introduced in 1994, the S&P SmallCap 600 is a widely followed benchmark of 600 U.S. small-cap companies selected by S&P Dow Jones Indices based on market capitalization, liquidity, shares available for public trading, and profitability criteria. Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “Inclusion in the S&P SmallCap 600 is a meaningful marker of how far Liquidia has come, and it is a credit to the entire team. It reflects the discipline and execution behind our progress and the foundation we have built through our commitment to patients, innovation and operational excellence. We are focused on the opportunities ahead as we continue our work to revolutionize care for patients with cha…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
Liquidia Corporation
LQDANASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On June 8, 2026, Liquidia Corporation, a Delaware corporation, issued a press release announcing that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
Company context
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, a drug approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). YUTREPIA is currently under development for other indications, including SSc-RP. The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.